29.10
+4.49%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tanvex BioPharma
Its shares trade on Taiwan Stock Exchange under the ticker 6541.TW. It has been listed since 13 August 2015. In the fiscal year to 31 December 2025, it reported revenue of TWD 401.0m and a net loss of TWD 1.50bn. At that date it held total assets of TWD 7.96bn and shareholders' equity of TWD 5.69bn.
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. The firm is developing and delivering biologic and biosimilar drugs to people.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Aug 2015
- Website
- tanvex.com ↗
Leadership
Pay as last reported
- Mr. Pao-Shi ShengChairman of the Board, since 2025
- Mr. Stephen LamChief Executive Officer, Director, since 2024
- Junyi LuanChief Financial Officer, Corporate Governance Officer
- Jennifer KuanDeputy General Manager-Operations
- Ms. Helena MakagiansarDeputy General Manager-LJB Production Development
- Mr. Mike ParkerSenior Deputy General Manager-Technology
- Mr. Yongjian WuDeputy General Manager-LJB Research & Development
- Mr. Kaiwen YangDeputy General Manager-LJB Production
- Marc GoemansChief Commercial Officer
- James WilliamsonHead of Accounting
- Mr. Allen ChaoDirector, since 2013
- Mr. Chi-Chuan ChenDirector, since 2013
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tanvex BioPharma Inc. operates a vertically integrated manufacturing platform for biopharmaceuticals.
- The company's product pipeline includes Neupogen (TX-01), Herceptin (TX-05), and Neulasta (TX-04).
- Tanvex BioPharma Inc. is listed on the Taiwan Stock Exchange with ticker 6541.TW.
Weaknesses
- The company is a clinical stage company with no mention of commercialized products.
- Tanvex BioPharma Inc. is based in George Town, Cayman Islands (KY), which may limit local market access.
- The firm's IPO occurred in August 2015, indicating a relatively young company in the biotechnology sector.
Opportunities
- The company's expertise in strain and cell-line development could expand into new biologic drug markets.
- Tanvex BioPharma Inc. has a pipeline of biosimilar drugs including Avastin (TX-16) and Perjeta (TX-52).
- The firm's focus on biologic and biosimilar drug development aligns with global healthcare trends.
Threats
- The biotechnology industry faces high regulatory hurdles for new drug approvals.
- Competition in the biosimilar market may intensify as more companies enter the sector.
- The company's clinical stage status means it faces significant development risks before commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.